J M Kirkwood
Affiliation: Harvard University
- High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801J M Kirkwood
Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
J Clin Oncol 19:2370-80. 2001....
- Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cellsH M Zarour
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Proc Natl Acad Sci U S A 97:400-5. 2000..Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4(+) T cell responses against melanoma in vivo...
- High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood
Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
J Clin Oncol 18:2444-58. 2000..Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs)...
- High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood
University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
J Clin Oncol 19:1430-6. 2001....
- gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
Br J Cancer 85:1738-45. 2001..Based on these data, these epitopes may serve as potent vaccine components to promote clinically-relevant Th1-type CD4+ T cell effector function in situ...
- IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitroL Vujanovic
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Gene Ther 13:798-805. 2006..Based on these results, we believe this modality may prove clinically useful as a vaccine platform to promote the recovery of tumor antigen-specific, Th1-type CD4(+) T-cell responses in patients with cancer...
- Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanomaS S Agarwala
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Oncologist 5:144-51. 2000..Therefore, TMZ is actively being investigated for the treatment and prevention of brain metastases in melanoma patients. TMZ may become an important part of treatment regimens for advanced metastatic melanoma...
- SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomasS J Moschos
Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
Oncogene 26:4216-25. 2007....
- Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690U N M Rao
Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213 2582, USA
J Clin Oncol 20:2053-7. 2002....
- Targeted therapy for malignant melanomaC K Brown
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, 200 Lothrop Street, N-758 MUH, Pittsburgh, PA 15213-2582, USA
Curr Oncol Rep 3:344-52. 2001..This work has furthered our understanding of the basis of malignancy, as well as the development of novel strategies aimed at targeting aberrant growth in melanoma...
- Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumoursH A Tawbi
Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Br J Cancer 105:773-7. 2011..Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first phase I experience of the novel O6-meG pseudosubstrate lomeguatrib, combined with dacarbazine...